エルロチニブ塩酸塩 (TARCEVA)
エルロチニブ塩酸塩 (TARCEVA) 物理性質
- 融点 :
- 223-225°C
- 貯蔵温度 :
- Inert atmosphere,Store in freezer, under -20°C
- 溶解性:
- DMSO に可溶 (加温により 18 mg/ml まで)。
- 外見 :
- 黄色い粉。
- 酸解離定数(Pka):
- pKa (25°): 5.42
- 色:
- 白またはオフホワイト
- 安定性::
- -20°C の DMSO 溶液で最大 3 か月間保存できます。
- InChI:
- InChI=1S/C22H23N3O4.ClH/c1-4-16-6-5-7-17(12-16)25-22-18-13-20(28-10-8-26-2)21(29-11-9-27-3)14-19(18)23-15-24-22;/h1,5-7,12-15H,8-11H2,2-3H3,(H,23,24,25);1H
- InChIKey:
- GTTBEUCJPZQMDZ-UHFFFAOYSA-N
- SMILES:
- C12C=C(OCCOC)C(OCCOC)=CC=1N=CN=C2NC1=CC=CC(=C1)C#C.Cl
- CAS データベース:
- 183319-69-9(CAS DataBase Reference)
安全性情報
- リスクと安全性に関する声明
- 危険有害性情報のコード(GHS)
Sフレーズ |
24/25 |
|
|
HSコード |
29335990 |
|
|
絵表示(GHS) |
|
注意喚起語 |
警告 |
危険有害性情報 |
コード |
危険有害性情報 |
危険有害性クラス |
区分 |
注意喚起語 |
シンボル |
P コード |
H413 |
長期的影響により水生生物に有害のおそれ |
水生環境有害性、慢性毒性 |
4 |
|
|
|
|
注意書き |
|
エルロチニブ塩酸塩 (TARCEVA) 価格
もっと(18)
メーカー |
製品番号 |
製品説明 |
CAS番号 |
包装 |
価格 |
更新時間 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBST-7799 |
Erlotinib, HCl |
183319-69-9 |
1g |
¥10000 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01COBST-7799 |
Erlotinib, HCl |
183319-69-9 |
5g |
¥15000 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01W0105-0911 |
エルロチニブ塩酸塩 98.0+% (HPLC)
Erlotinib Hydrochloride 98.0+% (HPLC) |
183319-69-9 |
100mg |
¥9150 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01W0105-0911 |
エルロチニブ塩酸塩 98.0+% (HPLC)
Erlotinib Hydrochloride 98.0+% (HPLC) |
183319-69-9 |
500mg |
¥37400 |
2024-03-01 |
購入 |
富士フイルム和光純薬株式会社(wako)
|
W01TRCT007500 |
Tarceva (エルロチニブ塩酸塩)
Tarceva (Erlotinib Hydrochloride) |
183319-69-9 |
500mg |
¥29400 |
2024-03-01 |
購入 |
エルロチニブ塩酸塩 (TARCEVA) 化学特性,用途語,生産方法
外観
白色~うすい褐色、結晶性粉末~粉末
溶解性
ジメチルスルホキシドに溶け、アセトン及び水にほとんど溶けない。
用途
上皮成長因子受容体(EGFR)
チロシンキナーゼの阻害剤です。EGFR 遺伝
子変異による、腫瘍細胞の増殖を抑制する作
用を示します。
効能
抗悪性腫瘍薬, 受容体チロシンキナーゼ阻害薬
商品名
タルセバ (中外製薬); タルセバ (中外製薬)
化学的特性
Off-White Solid
使用
Erlotinib hydrochloride (V), a quinazoline derived small
molecule inhibitor of epidermal growth factor receptor
(EDGFR) tyrosine kinase, was approved in November,
2004, for the treatment of advanced or metastatic non-smallcell
lung cancer. It belongs to the same class as gefitinib,another quinazoline approved for treatment of advanced lung
cancer, but with improved pharmacokinetic properties. The molecule was originated by Pfizer and development
initiated in collaboration with OSI, which assumed full
rights to the drug when Pfizer merged with Warner Lambert.
Subsequently, Genentech/Roche went into licensing
agreement with OSI to develop and market the drug in the
US and Worldwide.
定義
ChEBI: A quinazoline hydrochloride compound having a (3-ethynylphenyl)amino group at the 4-position and two 2-methoxyethoxy groups at the 6- and 7-positions.
一般的な説明
Erlotinib is available as 25-, 100-, and 150-mg tablets fororal administration and is used after failure of first-linetherapy in metastatic NSCLC and as first-line therapy incombination with gemcitabine in the treatment of metastaticpancreatic cancer, and in treating malignant gliomas.The structural similarity to gefitnib imparts similar pharmacokineticbehavior with bioavailability of 60% and proteinbinding of 93%. The agent is extensively metabolizedprimarily by CYP3A4. Three major metabolic pathwayshave been identified, involving oxidative-O-demethylationof the side chains followed by further oxidation to give thecarboxlic acids, oxidation of the acetylene functionalityto give a carboxylic acid, and aromatic hydroxylation ofthe phenyl ring para to the electron-donating nitrogen. Themetabolites are primarily eliminated in the feces, and theterminal half-life is 36 hours.The major toxicities seenwith the agent are dose-limiting skin rash and diarrhea.Other common adverse effects include shortness of breath,fatigue, and nausea.
エルロチニブ塩酸塩 (TARCEVA) 上流と下流の製品情報
原材料
準備製品
エルロチニブ塩酸塩 (TARCEVA) 生産企業
Global( 729)Suppliers
エルロチニブ塩酸塩 (TARCEVA) スペクトルデータ(1HNMR)
183319-69-9(エルロチニブ塩酸塩 (TARCEVA))キーワード:
- 183319-69-9
- ERLOTINIB HCL SALT
- ERLOTINIB HCL SALT :TARCEVA
- N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine, Hydrochloride Salt, OSI 774, Tarceva
- N-(3-Ethynylphenyl)-6,7-bis-(2-methoxyethoxy)-quinazolin-4-amine
- [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4yl]-(3-ethynyl-phenyl)-amine
- Tarceva HydrochlorideSee E625000
- 6,7-Bis(2-methoxyethoxy)-4-(3-ethynylanilino)quinazoline hydrochloride
- Erlotinib hydrochloride
- N-(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine hydrochloride
- Erlotinib HCl(TINIBS)
- erlotinib hydorchloride
- 6,7-BIS(2-METHOXYETHOXY)-4-(3-ETHYNYLANILINO)QUINAZOLINE HCL
- Erlotonid HCl
- 6,7-Bis(2-methoxyethoxy)-4-(3-
- 21 Erlotinib hydrochloride and Intermediate
- -(3-Ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine hydrochloride
- Erlotinib, Hydrochloride (Tarceva Hydrochloride)
- Tarceva Hydrochloride (Erlotinib Hydrochloride)
- Erlotinib Hydrochloride (Tarceva)
- Erlotinib, OS-774
- 4-(m-Ethynylanilino)-6,7-bis(2-methoxyethoxy)quinazoline monohydrochloride
- Tarceva (Erlotinib Hydrochloride)
- 4-QuinazolinaMine, n-(3-ethynylphenyl)-6,7-bis(2-Methoxyethoxy)-, hydrochloride
- Erlotinib HCL and InterMediate
- 4-QuinazolinaMine,N-(3-ethynylphenyl)-6,7-bis(2-Methoxyethoxy)-,hydrochloride(1:1)
- [6,7-Bis(2-Methoxyethoxy)quinazolin-4-yl]-(3-ethynylphenyl)aMine Hydrochloride
- CP 358774
- N-(3-Ethynylphenyl)-6,7-bis(2-Methoxyethoxy)-4-quinazolinaMine Hydrochloride
- OSI 774
- NSC718781
- エルロチニブ塩酸塩 (TARCEVA)
- エルロチニブ塩酸塩
- TARCEVA (エルロチニブ塩酸塩)
- エルロニチブ塩酸塩
- エルロチニブ塩酸塩 (JAN)